EP1646353A4 - Fusionsproteine zur behandlung des zns - Google Patents
Fusionsproteine zur behandlung des znsInfo
- Publication number
- EP1646353A4 EP1646353A4 EP04776038A EP04776038A EP1646353A4 EP 1646353 A4 EP1646353 A4 EP 1646353A4 EP 04776038 A EP04776038 A EP 04776038A EP 04776038 A EP04776038 A EP 04776038A EP 1646353 A4 EP1646353 A4 EP 1646353A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- cns
- treatment
- fusion proteins
- fusion
- proteins
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/51—Lyases (4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/88—Lyases (4.)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10184697.0A EP2354155B1 (de) | 2003-05-16 | 2004-05-17 | Fusionsproteine zur Behandlung des ZNS |
EP17164945.2A EP3210999B1 (de) | 2003-05-16 | 2004-05-17 | Fusionsproteine zur behandlung des zns |
ES17164945T ES2831031T3 (es) | 2003-05-16 | 2004-05-17 | Proteínas de fusión para el tratamiento del CNS |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US47123903P | 2003-05-16 | 2003-05-16 | |
US47123603P | 2003-05-16 | 2003-05-16 | |
US47130003P | 2003-05-16 | 2003-05-16 | |
US47124003P | 2003-05-16 | 2003-05-16 | |
US47437203P | 2003-05-29 | 2003-05-29 | |
PCT/US2004/015661 WO2004110359A2 (en) | 2003-05-16 | 2004-05-17 | Fusion proteins for the treatment of cns |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP10184697.0A Division EP2354155B1 (de) | 2003-05-16 | 2004-05-17 | Fusionsproteine zur Behandlung des ZNS |
EP17164945.2A Division EP3210999B1 (de) | 2003-05-16 | 2004-05-17 | Fusionsproteine zur behandlung des zns |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1646353A2 EP1646353A2 (de) | 2006-04-19 |
EP1646353A4 true EP1646353A4 (de) | 2008-06-04 |
Family
ID=33556640
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP04776038A Ceased EP1646353A4 (de) | 2003-05-16 | 2004-05-17 | Fusionsproteine zur behandlung des zns |
EP10184697.0A Expired - Lifetime EP2354155B1 (de) | 2003-05-16 | 2004-05-17 | Fusionsproteine zur Behandlung des ZNS |
EP17164945.2A Expired - Lifetime EP3210999B1 (de) | 2003-05-16 | 2004-05-17 | Fusionsproteine zur behandlung des zns |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP10184697.0A Expired - Lifetime EP2354155B1 (de) | 2003-05-16 | 2004-05-17 | Fusionsproteine zur Behandlung des ZNS |
EP17164945.2A Expired - Lifetime EP3210999B1 (de) | 2003-05-16 | 2004-05-17 | Fusionsproteine zur behandlung des zns |
Country Status (7)
Country | Link |
---|---|
EP (3) | EP1646353A4 (de) |
JP (5) | JP5399612B2 (de) |
AU (1) | AU2004247025B8 (de) |
CA (1) | CA2525782C (de) |
ES (1) | ES2831031T3 (de) |
MX (2) | MX351062B (de) |
WO (1) | WO2004110359A2 (de) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7666852B2 (en) * | 2002-04-22 | 2010-02-23 | Agenta Biotechnologies, Inc. | Wound and cutaneous injury healing with a nucleic acid encoding a proteoglycan polypeptide |
US8183350B2 (en) | 2002-05-04 | 2012-05-22 | Acorda Therapeutics, Inc. | Compositions and methods for promoting neuronal outgrowth |
US7959914B2 (en) | 2003-05-16 | 2011-06-14 | Acorda Therapeutics, Inc. | Methods of reducing extravasation of inflammatory cells |
JP2007532094A (ja) | 2003-05-16 | 2007-11-15 | アコーダ セラピューティクス、インク. | Cns治療用のプロテオグリカン分解変異体 |
JP4926962B2 (ja) * | 2004-05-18 | 2012-05-09 | アコーダ セラピューティクス、インク. | コンドロイチン分解酵素とその安定な製剤の精製法 |
WO2007038548A2 (en) | 2005-09-26 | 2007-04-05 | Acorda Therapeutics, Inc. | Compositions and methods of using chondroitinase abci mutants |
WO2007132481A2 (en) * | 2006-05-12 | 2007-11-22 | Bharat Biotech International Limited | Novel thrombolytic molecules and a process therefor |
WO2007136042A1 (ja) | 2006-05-19 | 2007-11-29 | Aichi Prefecture | 脳損傷改善剤 |
CA3086902C (en) * | 2006-10-10 | 2021-11-09 | Acorda Therapeutics, Inc. | Compositions and methods of using chondroitinase abci mutants |
WO2008061019A2 (en) * | 2006-11-14 | 2008-05-22 | Genentech, Inc. | Modulators of neuronal regeneration |
WO2008149428A1 (ja) * | 2007-06-05 | 2008-12-11 | Glycoscience Laboratories, Inc. | 自己免疫疾患、炎症及び神経疾患の治療剤及び予防剤 |
AU2015200220A1 (en) * | 2008-02-29 | 2015-02-12 | Acorda Therapeutics, Inc. | Method for achieving desired glial growth factor 2 plasma levels |
ES2811127T3 (es) * | 2008-02-29 | 2021-03-10 | Acorda Therapeutics Inc | Composiciones para lograr niveles plasmáticos deseados del factor 2 de crecimiento glial |
EP2603221A4 (de) * | 2010-08-13 | 2014-02-26 | Univ Georgetown | Ggf2 und verfahren zu seiner anwendung |
US9144601B2 (en) | 2011-09-15 | 2015-09-29 | Seikagaku Corporation | Skeletal muscle regeneration promoter |
GB201322396D0 (en) | 2013-12-18 | 2014-02-05 | Univ Nottingham | Transduction |
US11396529B2 (en) | 2020-11-12 | 2022-07-26 | National Sun Yat-Sen University | Isolated peptide, anti-cancer medicinal composition including the same and method of specifically reducing or inhibiting activities of cancer cells using the same |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000062067A1 (en) * | 1999-02-28 | 2000-10-19 | Washington University | Novel transduction molecules and methods for using same |
US6171575B1 (en) * | 1998-04-06 | 2001-01-09 | Shinichi Okuyama | Method of radioisotopic assessment of the integrity and function of the nose-brain barrier |
WO2002055684A2 (en) * | 2001-01-09 | 2002-07-18 | Univ Iowa Res Found | Synthetic proteins containing a protein transduction domain |
WO2002083179A2 (en) * | 2001-04-12 | 2002-10-24 | Bioaxone Therapeutique Inc. | Fusion proteins |
WO2003100031A2 (en) * | 2002-05-20 | 2003-12-04 | Board Of Regents, The University Of Texas System | Methods and compositions for delivering enzymes and nucleic acid molecules to brain, bone, and other tissues |
WO2004017044A2 (en) * | 2002-08-15 | 2004-02-26 | Acorda Therapeutics, Inc. | Chimeric protein |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5670617A (en) | 1989-12-21 | 1997-09-23 | Biogen Inc | Nucleic acid conjugates of tat-derived transport polypeptides |
US5804604A (en) | 1989-12-21 | 1998-09-08 | Biogen, Inc. | Tat-derived transport polypeptides and fusion proteins |
AU697156B2 (en) * | 1993-04-23 | 1998-10-01 | American Cyanamid Company | Cloning and expression of the chondroitinase I and II genes from (p. vulgaris) |
WO1995013091A1 (en) * | 1993-11-12 | 1995-05-18 | International Technology Management Associates, Ltd. | Methods of repairing connective tissues |
JPH07316068A (ja) * | 1994-05-25 | 1995-12-05 | Canji Inc | 腫瘍サプレッサー融合タンパク質 |
GB9622500D0 (en) * | 1996-10-29 | 1997-01-08 | Oxford Biomedica Ltd | Therapeutic gene |
US20010006630A1 (en) * | 1997-09-02 | 2001-07-05 | Oron Yacoby-Zeevi | Introducing a biological material into a patient |
AU765218B2 (en) * | 1999-03-16 | 2003-09-11 | Government of The United States of America, as represented by The Secretary Department of Health & Human Services, The National Institutes of Health, The | A novel chimeric protein for prevention and treatment of HIV infection |
SE9901428D0 (sv) * | 1999-04-21 | 1999-04-21 | Karolinska Innovations Ab | Amphibodies |
DE60019415T2 (de) * | 1999-06-08 | 2006-03-09 | Regeneron Pharmaceuticals, Inc. | Modifizierte chimärische polypeptide mit verbesserten pharmakokynetischen eigenschaften |
WO2001039795A2 (en) * | 1999-12-02 | 2001-06-07 | Ibex Technologies, Inc. | Attenuation of fibroblast proliferation |
KR20040021697A (ko) * | 2001-08-13 | 2004-03-10 | 유니버시티 오브 플로리다 리서치 파운데이션, 인크. | 신경 조직 복구를 증진시키는 물질 및 방법 |
GB0205022D0 (en) * | 2002-03-04 | 2002-04-17 | Univ Cambridge Tech | Materials and methods for the treatment of cns damage |
-
2004
- 2004-05-17 EP EP04776038A patent/EP1646353A4/de not_active Ceased
- 2004-05-17 EP EP10184697.0A patent/EP2354155B1/de not_active Expired - Lifetime
- 2004-05-17 ES ES17164945T patent/ES2831031T3/es not_active Expired - Lifetime
- 2004-05-17 CA CA2525782A patent/CA2525782C/en not_active Expired - Fee Related
- 2004-05-17 JP JP2006533212A patent/JP5399612B2/ja not_active Expired - Fee Related
- 2004-05-17 EP EP17164945.2A patent/EP3210999B1/de not_active Expired - Lifetime
- 2004-05-17 WO PCT/US2004/015661 patent/WO2004110359A2/en active Application Filing
- 2004-05-17 AU AU2004247025A patent/AU2004247025B8/en not_active Ceased
- 2004-05-17 MX MX2012003710A patent/MX351062B/es unknown
- 2004-05-17 MX MXPA05012306A patent/MXPA05012306A/es active IP Right Grant
-
2012
- 2012-09-27 JP JP2012215041A patent/JP5656314B2/ja not_active Expired - Fee Related
-
2014
- 2014-07-04 JP JP2014138911A patent/JP6141571B2/ja not_active Expired - Fee Related
-
2017
- 2017-02-21 JP JP2017030467A patent/JP6913428B2/ja not_active Expired - Lifetime
-
2020
- 2020-02-29 JP JP2020034479A patent/JP2020111578A/ja active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6171575B1 (en) * | 1998-04-06 | 2001-01-09 | Shinichi Okuyama | Method of radioisotopic assessment of the integrity and function of the nose-brain barrier |
WO2000062067A1 (en) * | 1999-02-28 | 2000-10-19 | Washington University | Novel transduction molecules and methods for using same |
WO2002055684A2 (en) * | 2001-01-09 | 2002-07-18 | Univ Iowa Res Found | Synthetic proteins containing a protein transduction domain |
WO2002083179A2 (en) * | 2001-04-12 | 2002-10-24 | Bioaxone Therapeutique Inc. | Fusion proteins |
WO2003100031A2 (en) * | 2002-05-20 | 2003-12-04 | Board Of Regents, The University Of Texas System | Methods and compositions for delivering enzymes and nucleic acid molecules to brain, bone, and other tissues |
WO2004017044A2 (en) * | 2002-08-15 | 2004-02-26 | Acorda Therapeutics, Inc. | Chimeric protein |
Non-Patent Citations (4)
Title |
---|
"ROUTE OF ADMINISTRATION - FDA", 11 January 2006 (2006-01-11), XP055243674 * |
BRADBURY E J ET AL: "Chondroitinase ABC promotes functional recovery after spinal cord injury", NATURE, NATURE PUBLISHING GROUP, LONDON, GB, vol. 416, 11 April 2002 (2002-04-11), pages 636 - 640, XP002245003, ISSN: 0028-0836 * |
FROM WIKIPEDIA: "Route of administration", 5 January 2016 (2016-01-05), XP055243671 * |
MCGEE A W ET AL: "The Nogo-66 receptor: focusing myelin inhibition of axon regeneration", TRENDS IN NEUROSCIENCE, ELSEVIER, AMSTERDAM, NL, vol. 26, no. 4, April 2003 (2003-04-01), pages 193 - 198, XP004418152, ISSN: 0166-2236 * |
Also Published As
Publication number | Publication date |
---|---|
JP5399612B2 (ja) | 2014-01-29 |
WO2004110359A2 (en) | 2004-12-23 |
MXPA05012306A (es) | 2006-04-18 |
JP6141571B2 (ja) | 2017-07-12 |
WO2004110359A3 (en) | 2006-08-17 |
JP2017125035A (ja) | 2017-07-20 |
AU2004247025A1 (en) | 2004-12-23 |
EP3210999A1 (de) | 2017-08-30 |
WO2004110359A9 (en) | 2006-02-16 |
JP2014221793A (ja) | 2014-11-27 |
EP2354155B1 (de) | 2017-05-03 |
JP5656314B2 (ja) | 2015-01-21 |
JP2013049677A (ja) | 2013-03-14 |
AU2004247025B2 (en) | 2011-06-23 |
ES2831031T3 (es) | 2021-06-07 |
AU2004247025B8 (en) | 2011-06-30 |
EP3210999B1 (de) | 2020-08-26 |
EP2354155A3 (de) | 2011-09-07 |
JP2007516229A (ja) | 2007-06-21 |
MX351062B (es) | 2017-09-29 |
CA2525782C (en) | 2019-02-05 |
EP2354155A2 (de) | 2011-08-10 |
JP6913428B2 (ja) | 2021-08-04 |
CA2525782A1 (en) | 2004-12-23 |
JP2020111578A (ja) | 2020-07-27 |
EP1646353A2 (de) | 2006-04-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL166751A0 (en) | Modified transferin-antibody fusion proteins | |
EP1688439A4 (de) | Zusammensetzung kondensierter proteine | |
IL173456A0 (en) | Process for the preparation of 4-amino-3-quinolinecarbonitriles | |
EP1543038A4 (de) | Proteinaufreinigung | |
HK1096096A1 (en) | Novel fused pyrrolocarbazoles | |
IL176385A0 (en) | Fused pyrrolocarbazoles and methods for the preparation thereof | |
EP1646353A4 (de) | Fusionsproteine zur behandlung des zns | |
IL176326A0 (en) | Process for the production of proteins | |
EP1549343A4 (de) | Verfahren zur behandlung von nephritis mit anti-pdgf-dd-antikörpern | |
IL175743A0 (en) | Process for the preparation of thiazolopyrimidines | |
ZA200605668B (en) | Fused pyrrolocarbazoles and methods for the preparation thereof | |
SI1656455T1 (sl) | Postopek za čiščenje rekombinantnih polipeptidov | |
GB0200689D0 (en) | Fusion proteins | |
HK1095145A1 (en) | Process for the preparation of n-arylmorpholinones n- | |
PL371583A1 (en) | Process for the preparation of 7alpha-methylsteroids | |
SG111997A1 (en) | Improved process for the preparation of polyalkylphenoxyaminoalkanes | |
IL164788A0 (en) | Process for the preparation of 3-isochromanone | |
GB0522915D0 (en) | Methods for recombinant immunoglobulin treatment | |
HK1087111A1 (en) | Process for the preparation of nicotinaldehydes | |
PL376745A1 (pl) | Proces oczyszczania białek wiążących TNF przy użyciu IMAC | |
GB0311108D0 (en) | Proteins | |
HU0300255D0 (en) | Process for the preparation of 2-phenyl-4-methyl-1-tosil-piperazine | |
SI1673365T1 (sl) | Postopek za pripravo Z-flupentiksola. | |
AU2003290331A8 (en) | Protein purification means | |
SI1395580T1 (en) | Method for the purification of triazolylmethylepoxides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20051214 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL HR LT LV MK |
|
PUAK | Availability of information related to the publication of the international search report |
Free format text: ORIGINAL CODE: 0009015 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C12P 21/06 20060101AFI20061005BHEP |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: GRUSKIN, ELLIOTT, A. Inventor name: IACI, JENNIFER Inventor name: ROY, GARGI Inventor name: ZIMBER, MICHAEL, P. Inventor name: CAGGIANO, ANTHONY, O. |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20080506 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 38/51 20060101ALI20080425BHEP Ipc: C12N 9/88 20060101ALI20080425BHEP Ipc: C12P 21/06 20060101AFI20061005BHEP Ipc: C07K 14/475 20060101ALI20080425BHEP |
|
17Q | First examination report despatched |
Effective date: 20080905 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R003 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED |
|
18R | Application refused |
Effective date: 20160923 |